SPRO - Latest News

Spero Therapeutics, Inc. (SPRO), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $141.3M. Trailing twelve-month P/E ratio is 6.23. Beta to the broader market is 1.43.

The article list below shows the most recent SPRO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent SPRO Headlines

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

globenewswire.com - May 13, 2026

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, wi

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

globenewswire.com - May 5, 2026

CAMBRIDGE, Mass. , May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc.

Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast

defenseworld.net - Mar 28, 2026

Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Free Report) are both small-cap medical companies, b

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

globenewswire.com - Mar 26, 2026

CAMBRIDGE, Mass. , March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

globenewswire.com - Mar 18, 2026

CAMBRIDGE, Mass. , March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.

How News Affects SPRO Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SPRO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked SPRO news questions

What is the latest SPRO news headline?
The most recent SPRO headline (May 13, 2026) is "Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
How fresh is the SPRO news on this page?
News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
What SPRO news moves options pricing?
Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
How can I track unusual SPRO options activity related to news?
Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.